Pathos AI Raises $365 Million to Power AI-Driven Cancer Drug Trials

Pathos AI, a Boston-based biotech company using AI to develop cancer treatments, has just raised $365 million in Series D funding.

This major investment will help the company push forward clinical trials of promising drugs, including cancer therapies originally developed by Novo Nordisk and Prelude Therapeutics.

With this new funding, Pathos AI now holds a valuation of $1.6 billion — proving that investors have strong confidence in AI’s potential to transform the future of cancer care.

What Is Pathos AI Working On?

At the top of Pathos’ priority list is a drug called pocenbrodib, originally created at Forma Therapeutics and later licensed from Novo Nordisk. The drug is designed to target prostate cancer and possibly other solid tumors.

In March 2025, Pathos started a Phase 1b/2a trial of pocenbrodib — testing it both alone and in combination with well-known cancer drugs like Zytiga, Lynparza, and Pluvicto in patients with advanced prostate cancer.

But that’s not all.

Pathos is also preparing trials for another promising treatment called P-500, a brain-penetrating drug designed to treat tough cancers like glioma and uveal melanoma. This drug was licensed from Prelude Therapeutics last year.

The Power of the PathOS Platform

What makes Pathos AI special is its PathOS Platform — an advanced system that uses AI and multimodal data (like imaging, genetics, and clinical info) to:

Find the right patients for trials
Speed up drug development
Improve accuracy and outcomes

CEO Iker Huerga, who recently took charge after working as a top AI leader at AstraZeneca, says the platform will “ensure the right therapies reach the patients who need them most.”